Search results for "POMA."

showing 10 items of 183 documents

Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia

2013

Abstract Background Cyto- and molecular-genetic abnormalities evaluated at initial diagnosis are the most powerful prognostic and in part also predictive markers in acute myeloid leukemia (AML) with regard to achievement of complete remission (CR) and survival. Nonetheless, after relapse the prognostic impact of clinical characteristics and genetic abnormalities assessed at initial diagnosis with respect to achievement of subsequent CR and survival are less clear. Aims To evaluate the probability of CR achievement and survival in relapsed AML patients in correlation to clinical characteristics and genetic abnormalities assessed at initial diagnosis as well as treatment strategy. Methods The…

Acute promyelocytic leukemiaOncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentImmunologySalvage therapyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseasePomalidomideBiochemistryChemotherapy regimenSurgeryInternal medicineCEBPACytarabineMedicinebusinessmedicine.drugBlood
researchProduct

Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

2013

Abstract Background Overall survival (OS) in acute myeloid leukemia (AML) treated with intensive chemotherapy has improved over the last 20 year especially in younger adults (18-60 years) but still remains poor in older patients (>60 years) (Döhner et al. Blood 2010). The German-Austrian AMLSG performed controlled prospective treatment trials since 1993 starting with a risk-adapted approach (phase I, 1993-1997), followed by randomized and risk-adapted treatment strategies based on cytogenetic risk groups (phase II, 1997-2002); since 2003 addition of differentiating agents and HiDAC inhibitors to intensive induction therapy was evaluated (phase III, 2003-2007). Of note, until 2007 younger…

Acute promyelocytic leukemiamedicine.medical_specialtyPediatricsmedicine.medical_treatmentImmunologyHematopoietic stem cell transplantationBiochemistry03 medical and health sciences0302 clinical medicineInternal medicinemedicineMyelofibrosisNeoadjuvant therapy030304 developmental biology0303 health sciencesChemotherapybusiness.industryMortality rateCell BiologyHematologymedicine.diseasePomalidomideChemotherapy regimen3. Good healthbusiness030215 immunologymedicine.drugBlood
researchProduct

Trattamento laparoscopico del Mielolipoma surrenalico: caso clinico e revisione della letteratura.

2006

Adrenal myelolipoma is a rare benign, non-functioning tumor consisting of fat and hematopoietic tissues. In January 2005 we had observed an adrenal myelolipoma in 70 year old man. During the follow-up for bladder urothelioma, an abdominal CT revaled a well delineated 4x4 cm homogeneous fatty mass in the right suprarenal area with negative attenuation values. The functional study of adrenal gland was normal. The patient underwent videolaparoscopic right adrenalectomy (Gagner technique). Postoperative course was uneventful. The istological diagnosis showed adrenal myelolipoma. We conclude that videolaparoscopic adrenalectomy should be considered the gold standard treatment for benign adrenal …

Adrenal myelolipoma Gagner technique bladder urothelioma videolaparoscopic adrenalectomy
researchProduct

Post-traumatic lipoma of the parotid gland: case report

2008

The incidence of lipoma among parotid tumours ranges from 0.6% to 4.4%, with most series reporting an incidence of 1%. The most common origin of these tumours, in the parotid gland, is from the superficial lobe and, only rarely, from the deep lobe. Lipomas, upon clinical history, are found to be most frequently related to an episode of trauma. Computed Tomography scan and Magnetic Resonance Imaging can lead to a pre-operative diagnosis of lipoma. The case is described of lipoma of the superficial lobe of the parotid gland.

AdultFacial ParalysisMagnetic Resonance ImagingParotid Neoplasmsbody regionsstomatognathic diseasesFacial Paralysis Bites and Stings Parotid Neoplasms Lipomastomatognathic systemCase reportotorhinolaryngologic diseasesHumansFemaleBites and StingsLipoma
researchProduct

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome

2008

Abstract Introduction: Magnesium plays a role in a large number of cellular metabolic reactions. Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transport in the kidney. We designed this trial to investigate if Mg2+ serum level modifications may be related with clinical response and outcome in advanced colorectal cancer patients during treatment with cetuximab plus irinotecan. Experimental Design: Sixty-eight heavily pretreated metastatic colorectal cancer patients were evaluated for Mg2+ serum levels at the following time points: before; 6 hours; and 1, 7, 14, 21, 50, and 92 days after the start of treatment. Results: Basal Mg2+ median levels were significan…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerCetuximabmagnesiumcolorectal cancerAntibodies Monoclonal HumanizedIrinotecanGastroenterologyHypomagnesemiaBasal (phylogenetics)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMagnesiumEpidermal growth factor receptorNeoplasm MetastasisAgedAged 80 and overCetuximabbiologybusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseIrinotecanGene Expression Regulation NeoplasticEndocrinologyTreatment OutcomeOncologyMonoclonalbiology.proteinDisease ProgressionCamptothecinFemalebusinessColorectal Neoplasmsmedicine.drug
researchProduct

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epider…

2011

Purpose We conducted a phase I dose-escalation study to characterize the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic properties of RG7160 (GA201), a humanized and glycoengineered immunoglobulin G1 anti–epidermal growth factor receptor (EGFR) monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity. Patients and Methods Seventy-five patients with advanced EGFR-positive solid tumors received RG7160 (50 to 1,400 mg) administered every week, every 2 weeks, or every 3 weeks. Dose escalation followed a three-plus-three trial design. Results No maximum-tolerated dose was reached for any dosing schedule. Common adverse events (AEs) included rash (80% of patien…

AdultMaleCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedGastroenterologyHypomagnesemiaCohort StudiesYoung AdultPharmacokineticsGrowth factor receptorNeoplasmsInternal medicineHumansMedicineDosingEpidermal growth factor receptorAdverse effectAgedGlycoproteinsAged 80 and overDose-Response Relationship Drugbiologybusiness.industryMiddle Agedmedicine.diseaseRashErbB ReceptorsOncologyPharmacodynamicsbiology.proteinFemalemedicine.symptombusinessJournal of Clinical Oncology
researchProduct

Stability in MMPI among adoptees with high and low genetic risk for schizophrenia and with low Communication Deviance of their adoptive parents.

2013

Abstract Stability has been considered an important aspect of vulnerability to schizophrenia. The temporal stability of the scales in the Minnesota Multiphasic Personality Inventory (MMPI) was examined, using adoptees from the Finnish Adoptive Family Study of Schizophrenia. Adoptees who were high-risk (HR) offspring of biological mothers having a schizophrenia spectrum disorder ( n =28) and low-risk (LR) controls ( n =46) were evaluated using 15 MMPI scales at the initial assessment (HR, mean age 24 years; LR, mean age 23 years) and at the follow-up assessment after a mean interval of 11 years. Stability of the MMPI scales was also assessed in the groups of adoptees, assigned according to t…

AdultMaleParentsParanoid schizophreniaAdolescentHostilityAdoption studyEnvironmentDevelopmental psychologyYoung AdultCommunication devianceMinnesota Multiphasic Personality InventoryMMPIPsychoticismmental disordersAdoptionmedicineHumansta515Biological PsychiatryFinlandAnalysis of VarianceCommunicationmedicine.diseasePsychiatry and Mental healthHypomaniaSchizophreniaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyPersonalityPsychiatry research
researchProduct

Ruptured angiomyolipoma of the kidney: a rare differential diagnosis of flank pain.

2017

Angiomyolipomas (AMLs) of the kidney are typically benign and rare, with an incidence of 2% of all renal masses [1]. They are associated with tuberous sclerosis in about 20% of cases. If ruptured, ...

AdultMalemedicine.medical_specialtyAngiomyolipomaFlank painUrologyAngiomyolipoma030232 urology & nephrologyUreteral stoneFlank PainDiagnosis Differential03 medical and health sciencesTuberous sclerosis0302 clinical medicinemedicineHumansKidneyRupture Spontaneousbusiness.industryIncidence (epidemiology)food and beveragesmedicine.diseaseKidney NeoplasmsSurgeryTomography x ray computedmedicine.anatomical_structureNephrology030220 oncology & carcinogenesisRadiologyDifferential diagnosisbusinessTomography X-Ray ComputedScandinavian journal of urology
researchProduct

Oral lipomas in a Brazilian population : a 10-year study and analysis of 450 cases reported in the literature

2009

Objectives: Lipomas are common benign mesenchymal neoplasms that rarely occur in the oral cavity and correspond to less than 4.4% of all benign oral soft tissue tumors. This study describes the clinical, radiological and histological features of cases of oral lipomas seen over a period of 10 years and compared the findings with those reported in the literature. Study Design: All cases of oral lipomas seen between 1999 and 2009 were retrieved from the archives of the Stomatology Division of the Federal University of Ceará, Brazil. Age, gender, tumor location, clinical findings, duration, histological subtypes, and treatment outcome were recorded. In addition, the English-language literature …

AdultMalemedicine.medical_specialtyTime FactorsAngiolipomaRadiographyYoung AdultmedicineHumansOral mucosaYoung adultGeneral DentistryAgedFibrolipomabusiness.industrySoft tissueLipomaMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Surgerystomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryBrazilian populationFemaleMouth NeoplasmsLipomabusinessBrazil
researchProduct

A case of lipogranulomatosis Farber: some clinical and ultrastructural aspects

1985

A 20-month-old girl showed typical clinical signs of Farber disease: hoarseness since birth, and periarticular subcutaneous painful nodules. Complete deficiency of acid ceramidase activity was found in cultured skin fibroblasts. An electron microscopic examination of a dermal nodule disclosed pathognomonic tubular inclusions in histiocytes. In epidermal cells zebra-body-like and needle-like lysosomal inclusions were found. Their ultrastructure is different from that of the intrahistiocytic lysosomal inclusions. Probably three clinical types of Farber disease may be distinguished according to the symptomatology and the course of the disease: a severe type, an intermediate type and a relative…

AdultPathologymedicine.medical_specialtyAcid CeramidaseAmidohydrolasesPathognomonicArthropathyCeramidasesmedicineHumansLipomatosisLymphocytesHistiocyteSkinFarber diseaseGranulomaHoarsenessbusiness.industryClinical coursemedicine.diseaseIntermediate typeAcid CeramidasePediatrics Perinatology and Child HealthUltrastructureFemaleJoint DiseasesbusinessEuropean Journal of Pediatrics
researchProduct